Current status and perspectives of the immunotherapy of leishmaniasis

Keyphrases

• Recombinant 100%
• Leishmania Major 100%
• Leishmaniasis 100%
• Prophylactic Vaccine 100%
• Phosphoinositide Lipid 100%
• Recent Advances 50%
• Immunization 50%
• Lymphocytes 50%
• Granulocyte Colony-stimulating Factor (G-CSF) 50%
• Immunotherapeutics 50%
• Next-generation Vaccines 50%
• Immunology 50%
• Immunogenic 50%
• Preventive Vaccine 50%
• Immunomodulator 50%
• Brazil 50%
• Leishmania 50%
• Specific Antigen 50%
• Alternative Therapy 50%
• Antileishmanial 50%
• Promastigote 50%
• Squalene 50%
• Thiol Antioxidant 50%
• Immunochemotherapy 50%
• Live Attenuated 50%
• DNA Vaccine 50%
• Minas Gerais State 50%
• Stress Inducible Protein 1 50%
• Innovative Therapies 50%
• Recombinant Fusion Proteins 50%
• Leishmania Vaccine 50%
• Major Stress 50%
• Living Dead 50%
• L. Infantum 50%
• Initiation Factors 50%

Immunology and Microbiology

• Leishmaniasis 100%
• Immunotherapy 100%
• Leishmania Vaccine 100%
• Immunomodulating Drugs 50%
• Phosphoryl Lipid A 50%
• Infectious Disease 25%
• Mycobacterium Bovis BCG 25%
• Granulocyte Macrophage Colony-Stimulating Factor 25%
• Antigen Specificity 25%
• Leishmania 25%
• Promastigote 25%
• Immunology 25%
• Initiation Factor 25%
• Lymphocyte 25%
• Infection 25%
• DNA Immunization 25%
• Parasite 25%